An FDA official, whose office was involved in the recent controversial approval review of Bristol-Myers Squibb’s Pargluva, has announced his resignation to join private industry, The New York Times reports.
David Orloff, a division director who oversees the review of drugs to treat metabolic and endocrine disorders, is set to join Medpace, a contract research organization that runs clinical drug trials.
Orloff told the Times his decision to leave after 11 years at the FDA, with five of them as division director, was not related to any problems or frustrations, but reflected a new opportunity.
Orloff’s departure from the FDA will be the third by a ranking agency official since the summer. In September, FDA commissioner Lester Crawford resigned for reasons yet to be fully explained, and in August, Susan Wood, the agency’s top women’s health official, resigned in protest over delays in an approval decision for the OTC sale of Barr’s Plan B contraceptive
Top FDA staffer becomes third to resign since August
An FDA official, whose office was involved in the recent controversial approval review of Bristol-Myers Squibb’s Pargluva, has announced his resignation to join private industry, The New York Times reports.
